Evidence map›Paper›PMID 39861826›Full record

ArticleViruses2024

The Ability of Combined Flavonol and Trihydroxyorganic Acid to Suppress SARS-CoV-2 Reproduction.

Andrey Bogoyavlenskiy, Pavel Alexyuk, Madina Alexyuk, Vladimir Berezin, Irina Zaitseva, Elmira Omirtaeva, Adolat Manakbayeva, Yergali Moldakhanov, Elmira Anarkulova, Anar Imangazy and 4 more

Abstract read
In one paragraph

Article in Viruses, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Andrey BogoyavlenskiyResearch and Production Center for Microbiology and Virology, Almaty 050010, Kazakhstan.
Pavel AlexyukResearch and Production Center for Microbiology and Virology, Almaty 050010, Kazakhstan.
Madina AlexyukResearch and Production Center for Microbiology and Virology, Almaty 050010, Kazakhstan.
Vladimir BerezinResearch and Production Center for Microbiology and Virology, Almaty 050010, Kazakhstan.
Irina ZaitsevaResearch and Production Center for Microbiology and Virology, Almaty 050010, Kazakhstan.
Elmira OmirtaevaResearch and Production Center for Microbiology and Virology, Almaty 050010, Kazakhstan.
Adolat ManakbayevaResearch and Production Center for Microbiology and Virology, Almaty 050010, Kazakhstan.ORCID 0000-0003-3256-3484
Yergali MoldakhanovResearch and Production Center for Microbiology and Virology, Almaty 050010, Kazakhstan.
Elmira AnarkulovaResearch and Production Center for Microbiology and Virology, Almaty 050010, Kazakhstan.ORCID 0000-0003-1875-177X
Anar ImangazyResearch and Production Center for Microbiology and Virology, Almaty 050010, Kazakhstan.
Kuralay AkanovaResearch and Production Center for Microbiology and Virology, Almaty 050010, Kazakhstan.
Zhumagali KoshemetovScientific Research Institute for Biological Safety Problems, Ministry of Health of Kazakhstan, Almaty 080409, Kazakhstan.
Nurkul OrazymbetovaScientific Research Institute for Biological Safety Problems, Ministry of Health of Kazakhstan, Almaty 080409, Kazakhstan.
Bakyt UmuraliyevScientific Research Institute for Biological Safety Problems, Ministry of Health of Kazakhstan, Almaty 080409, Kazakhstan.

Funding

Ministry of Science and Higher Education of the Republic of Kazakhstan AP19678025, BR10965178Ministry of Science and Higher Education of the Republic of Kazakhstan Grant No. AP19678025 and BR10965178
6 · The paper itself

Abstract

The global burden of COVID-19 continues to rise, and despite significant progress in vaccine development, there remains a critical need for effective treatments for the severe inflammation and acute lung injury associated with SARS-CoV-2 infection. In this study, we explored the antiviral properties of a plant-derived complex consisting of flavonol and hydroxyorganic acid compounds. Our research focused on the ability of the flavonol and hydroxyorganic acid complex to suppress the activity of several key proteins involved in the replication and maturation of SARS-CoV-2. These proteins include ACE2 protein, HRV 3C Protease, and Mpro (Main Protease). It was shown that the plant-based complex effectively inhibited the activity of these viral proteins. In addition to its effects on viral proteins, the flavonol and hydroxyorganic acid complex were shown to suppress viral replication in Vero E6 cells. At a dose of 22 μg/mL, the drug demonstrated maximum antiviral activity, significantly reducing the replication of SARS-CoV-2 in vitro. In preliminary studies, the complex showed both prophylactic and therapeutic potential, suggesting that it may be useful for preventing infection, as well as reducing the severity of disease once an individual has been infected with SARS-CoV-2. Based on the compelling results of this study, we propose the flavonol and hydroxyorganic acid complex as a potential therapeutic compound for SARS-CoV-2. Its ability to inhibit key viral proteins, suppress viral replication and exhibit protective and therapeutic effects positions it as a valuable candidate for further research and clinical evaluation. As the global fight against SARS-CoV-2 continues, plant-based therapies like this complex could complement existing treatments and provide new options for managing and treating the disease.

Indexed as

Antiviral AgentsCOVID-19 Drug TreatmentFlavonolsSARS-CoV-2Virus ReplicationAngiotensin-Converting Enzyme 2AnimalsChlorocebus aethiopsCoronavirus 3C ProteasesCOVID-19HumansVero CellsAngiotensin-Converting Enzyme 2Antiviral AgentsCoronavirus 3C ProteasesFlavonolsantiviral activityflavonolplant metaboliteSARS-CoV-2trihydroxyorganic acid

Identifiers

PMID39861826
PMCPMC11769457

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.